DOACs: Rivaroxaban, Dabigatran, Apixaban + Standard of care (Warfarin)
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
20
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Anticoagulation
Conditions
Anticoagulation
Trial Timeline
Jun 15, 2016 → Jun 30, 2017
NCT ID
NCT03684395About DOACs: Rivaroxaban, Dabigatran, Apixaban + Standard of care (Warfarin)
DOACs: Rivaroxaban, Dabigatran, Apixaban + Standard of care (Warfarin) is a pre-clinical stage product being developed by Bayer for Anticoagulation. The current trial status is completed. This product is registered under clinical trial identifier NCT03684395. Target conditions include Anticoagulation.
Hype Score Breakdown
Clinical
5
Activity
2
Company
7
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03684395 | Pre-clinical | Completed |
Competing Products
7 competing products in Anticoagulation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Apixaban | Pfizer | Approved | 84 |
| VKA + Apixaban + dabigatran + rivaroxaban | Bristol Myers Squibb | Pre-clinical | 22 |
| Apixaban | Bristol Myers Squibb | Pre-clinical | 22 |
| Apixaban + Cofact (4-Factor PCC) + Beriplex P/N (4-Factor PCC) + Placebo (Saline solution) | Bristol Myers Squibb | Phase 1 | 32 |
| four factor prothrombin complex concentrate | CSL | Approved | 84 |
| Prismocitrate 18 | Baxter | Phase 3 | 74 |
| Prismocitrate 18 | Baxter | Phase 3 | 74 |